Overview

PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

PTK is an investigational new drug that has been shown in early laboratory studies to prevent the formation of new blood vessels that allow the tumor to grow. These studies have shown that the study drug can potentially improve the effectiveness of additional radiation and chemotherapy. With this study, we would like to examine the effects of PTK when used in combination with radiation therapy and the anti-cancer drug temozolomide, the standard treatment for patients with newly diagnosed glioblastoma. We would also like to learn how the study drug is absorbed, distributed, and cleared from the body.

Phase:

Phase 1

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborators:

Dana-Farber Cancer Institute
Novartis

Treatments:

Dacarbazine
Temozolomide
Vatalanib